These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15314497)

  • 41. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].
    Horneff G
    Z Rheumatol; 2006 Mar; 65(2):152-6, 158. PubMed ID: 16372138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biologic targeted therapies in pediatric rheumatology.
    Guillaume-Czitrom S;
    Joint Bone Spine; 2014 Feb; 81 Suppl 1():2-48. PubMed ID: 24661916
    [No Abstract]   [Full Text] [Related]  

  • 46. [Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group Pediatric Rheumatology Austria].
    Niehues T; Horneff G; Michels H; Sailer Höck M; Schuchmann L
    Z Rheumatol; 2004 Apr; 63(2):147-58. PubMed ID: 15112095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Graudal N; Jürgens G
    Arthritis Care Res (Hoboken); 2013 May; 65(5):832. PubMed ID: 23097263
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapeutic strategies: Ways to remission].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):386-7. PubMed ID: 26085071
    [No Abstract]   [Full Text] [Related]  

  • 49. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
    Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
    Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Career lifetime advances in rheumatology.
    Scott DL
    Clin Med (Lond); 2010 Apr; 10(2):156-9. PubMed ID: 20437989
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
    Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
    Ruperto N; Martini A
    Georgian Med News; 2008 Mar; (156):68-74. PubMed ID: 18403813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.